A new trading day began on Friday, with Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) stock price down -3.62% from the previous day of trading, before settling in for the closing price of $43.65. RARE’s price has ranged from $37.02 to $60.37 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 53.47%. Meanwhile, its annual earnings per share averaged 23.87%. With a float of $86.37 million, this company’s outstanding shares have now reached $92.24 million.
Let’s determine the extent of company efficiency that accounts for 1276 employees. In terms of profitability, gross margin is 82.86%, operating margin of -102.49%, and the pretax margin is -107.33%.
Ultragenyx Pharmaceutical Inc (RARE) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ultragenyx Pharmaceutical Inc is 6.47%, while institutional ownership is 95.37%. The most recent insider transaction that took place on Dec 30 ’24, was worth 495,231. In this transaction President & CEO of this company sold 11,727 shares at a rate of $42.23, taking the stock ownership to the 2,183,985 shares. Before that another transaction happened on Dec 30 ’24, when Company’s Officer proposed sale 11,727 for $42.23, making the entire transaction worth $495,264.
Ultragenyx Pharmaceutical Inc (RARE) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.87% per share during the next fiscal year.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Here are Ultragenyx Pharmaceutical Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.46, a number that is poised to hit -1.36 in the next quarter and is forecasted to reach -5.12 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
Looking closely at Ultragenyx Pharmaceutical Inc (NASDAQ: RARE), its last 5-days average volume was 1.2 million, which is a drop from its year-to-date volume of 1.26 million. As of the previous 9 days, the stock’s Stochastic %D was 49.65%. Additionally, its Average True Range was 1.82.
During the past 100 days, Ultragenyx Pharmaceutical Inc’s (RARE) raw stochastic average was set at 9.94%, which indicates a significant decrease from 32.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.81% in the past 14 days, which was lower than the 33.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $46.67, while its 200-day Moving Average is $47.60. However, in the short run, Ultragenyx Pharmaceutical Inc’s stock first resistance to watch stands at $43.33. Second resistance stands at $44.60. The third major resistance level sits at $45.47. If the price goes on to break the first support level at $41.19, it is likely to go to the next support level at $40.32. Should the price break the second support level, the third support level stands at $39.05.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Key Stats
With a market capitalization of 3.88 billion, the company has a total of 92,344K Shares Outstanding. Currently, annual sales are 434,250 K while annual income is -606,640 K. The company’s previous quarter sales were 139,490 K while its latest quarter income was -133,520 K.
